We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
Read MoreHide Full Article
Thermo Fisher Scientific Inc.'s (TMO - Free Report) fourth-quarter 2020 adjusted earnings per share of $7.09 beat the Zacks Consensus Estimate by 3.4%. The figure surged 99.7% year over year. The adjusted number excludes certain non-recurring expenses including asset amortization costs and certain restructuring costs.
On a reported basis, earnings per share were $6.24 compared with $2.49 a year ago.
Significant COVID-19 led business expansion as well as the company’s base business growth contributed to such a stunning bottom-line performance.
For the full year, adjusted earnings were $19.55 per share, reflecting a 58.3% rise from the year-ago period. It also beat the Zacks Consensus Estimate by 1.1%.
Revenues in the quarter under review grossed $10.55 billion, up 54.5% year over year. The top line exceeded the Zacks Consensus Estimate by 2.6%.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
In the fourth quarter, the company generated $3.2 billion of COVID-19 response revenues and reported accelerated growth in its base business.
Total revenues for 2020 were $32.2 billion, a 26.3% rise from the year-ago period. This came ahead of the Zacks Consensus Estimate by 4.3%.
Quarter in Detail
Organic revenues in the reported quarter grew 51% year over year. Favorable currency translation increased revenues by 3%.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Revenues at the Life Sciences Solutions segment (41.4% of total revenues) improved 138% year over year to $4.37 billion while Analytical Instruments Segment sales (15.5%) rose 8% to $1.64 billion.
Revenues at the Laboratory Products and Services segment (34.3%) rose 28.8% to $3.62 billion. The Specialty Diagnostics segment (18.6%) recorded 109% year-over-year rise in revenues to $1.97 billion.
Gross margin of 53.9% in the fourth quarter expanded 761 basis points (bps) year over year on 79.9% rise in gross profits. Adjusted operating margin for the quarter came in at 33.3%, reflecting an expansion of 858 bps.
The company exited 2020 with cash and cash equivalents of $10.33 billion compared with $7.54 billion at the end of the third quarter. Full-year net cash provided by operating activities was $8.29 billion compared with $4.97 billion a year ago.
Guidance
The company stated that it will come up with its 2021 financial guidance on its earnings conference call.
Bottom Line
Thermo Fisher ended the fourth quarter as well as full-year 2020 with better-than-expected numbers. The company delivered an outstanding quarterly performance, leveraging on its capacity to extend support amid the pandemic. In the quarter, it generated $3.2 billion of COVID-19 related revenues.
We are encouraged about the exceptionally strong year-over-year revenue growth at Life Sciences Solutions and Specialty Diagnostics segments. Meanwhile, margin expansion in the fourth quarter was encouraging.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are IDEXX Laboratories, Inc. (IDXX - Free Report) , Align Technology, Inc. (ALGN - Free Report) and Omnicell, Inc. (OMCL - Free Report) .
The Zacks Consensus Estimate for IDEXX’s fourth-quarter 2020 revenues is pegged at $679.3 million, suggesting a year-over-year improvement of 12.2%. The same for EPS stands at $1.43, indicating growth of 37.5% from the year-ago reported figure. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Align Technology’s fourth-quarter 2020 revenues is pegged at $781.9 million, implying 20.3% increase from the year-earlier reported figure. The same for EPS stands at $2.13, indicating growth of 39.2% from the year-ago reported figure. The company currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for Omnicell’s fourth-quarter 2020 EPS is currently pegged at 79 cents, indicating growth of 2.6% from the year-ago reported figure. The company currently sports a Zacks Rank #1.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Shutterstock
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
Thermo Fisher Scientific Inc.'s (TMO - Free Report) fourth-quarter 2020 adjusted earnings per share of $7.09 beat the Zacks Consensus Estimate by 3.4%. The figure surged 99.7% year over year. The adjusted number excludes certain non-recurring expenses including asset amortization costs and certain restructuring costs.
On a reported basis, earnings per share were $6.24 compared with $2.49 a year ago.
Significant COVID-19 led business expansion as well as the company’s base business growth contributed to such a stunning bottom-line performance.
For the full year, adjusted earnings were $19.55 per share, reflecting a 58.3% rise from the year-ago period. It also beat the Zacks Consensus Estimate by 1.1%.
Revenues in the quarter under review grossed $10.55 billion, up 54.5% year over year. The top line exceeded the Zacks Consensus Estimate by 2.6%.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
In the fourth quarter, the company generated $3.2 billion of COVID-19 response revenues and reported accelerated growth in its base business.
Total revenues for 2020 were $32.2 billion, a 26.3% rise from the year-ago period. This came ahead of the Zacks Consensus Estimate by 4.3%.
Quarter in Detail
Organic revenues in the reported quarter grew 51% year over year. Favorable currency translation increased revenues by 3%.
Thermo Fisher operates under four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Revenues at the Life Sciences Solutions segment (41.4% of total revenues) improved 138% year over year to $4.37 billion while Analytical Instruments Segment sales (15.5%) rose 8% to $1.64 billion.
Revenues at the Laboratory Products and Services segment (34.3%) rose 28.8% to $3.62 billion. The Specialty Diagnostics segment (18.6%) recorded 109% year-over-year rise in revenues to $1.97 billion.
Gross margin of 53.9% in the fourth quarter expanded 761 basis points (bps) year over year on 79.9% rise in gross profits. Adjusted operating margin for the quarter came in at 33.3%, reflecting an expansion of 858 bps.
The company exited 2020 with cash and cash equivalents of $10.33 billion compared with $7.54 billion at the end of the third quarter. Full-year net cash provided by operating activities was $8.29 billion compared with $4.97 billion a year ago.
Guidance
The company stated that it will come up with its 2021 financial guidance on its earnings conference call.
Bottom Line
Thermo Fisher ended the fourth quarter as well as full-year 2020 with better-than-expected numbers. The company delivered an outstanding quarterly performance, leveraging on its capacity to extend support amid the pandemic. In the quarter, it generated $3.2 billion of COVID-19 related revenues.
We are encouraged about the exceptionally strong year-over-year revenue growth at Life Sciences Solutions and Specialty Diagnostics segments. Meanwhile, margin expansion in the fourth quarter was encouraging.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are IDEXX Laboratories, Inc. (IDXX - Free Report) , Align Technology, Inc. (ALGN - Free Report) and Omnicell, Inc. (OMCL - Free Report) .
The Zacks Consensus Estimate for IDEXX’s fourth-quarter 2020 revenues is pegged at $679.3 million, suggesting a year-over-year improvement of 12.2%. The same for EPS stands at $1.43, indicating growth of 37.5% from the year-ago reported figure. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Align Technology’s fourth-quarter 2020 revenues is pegged at $781.9 million, implying 20.3% increase from the year-earlier reported figure. The same for EPS stands at $2.13, indicating growth of 39.2% from the year-ago reported figure. The company currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for Omnicell’s fourth-quarter 2020 EPS is currently pegged at 79 cents, indicating growth of 2.6% from the year-ago reported figure. The company currently sports a Zacks Rank #1.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>